Inhibition of calcium-stimulated adenylyl cyclase subtype 1 (AC1) for the treatment of pain and anxiety symptoms in Parkinson’s disease mice model
Molecular Pain · 2024
DOI: 10.1177/17448069241266683 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pain, 2024. Verfasst von Zhaoxiang Zhou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Adenylyl Cyclases, Anxiety, Disease Models, Animal, Mice, Inbred C57BL. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: A technology Project of Guangzhou, Canadian Institute for Health Research (CIHR) Project.
Abstract (Originalsprache)
Pain and anxiety are two common and undertreated non-motor symptoms in Parkinson’s disease (PD), which affect the life quality of PD patients, and the underlying mechanisms remain unclear. As an important subtype of adenylyl cyclases (ACs), adenylyl cyclase subtype 1 (AC1) is critical for the induction of cortical long-term potentiation (LTP) and injury induced synaptic potentiation in the cortical areas including anterior cingulate cortex (ACC) and insular cortex (IC). Genetic deletion of AC1 or pharmacological inhibition of AC1 improved chronic pain and anxiety in different animal models. In this study, we proved the motor deficit, pain and anxiety symptoms of PD in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice model. As a lead candidate AC1 inhibitor, oral administration (1 dose and seven doses) of NB001 (20 and 40 mg/kg) showed significant analgesic effect in MPTP-treated mice, and the anxiety behavior was also reduced (40 mg/kg). By using genetic knockout mice, we found that AC1 knockout mice showed reduced pain and anxiety symptoms after MPTP administration, but not AC8 knockout mice. In summary, genetic deletion of AC1 or pharmacological inhibition of AC1 improved pain and anxiety symptoms in PD model mice, but didn’t affect motor function. These results suggest that NB001 is a potential drug for the treatment of pain and anxiety symptoms in PD patients by inhibiting AC1 target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
- Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
- Department of Exercise & Health Science, Xi'an Physical Education University, Xi'an, China.
- Zhuomin Institute of Brain Research, Qingdao, China.
ORCID-Profile: Zhaoxiang Zhou, Qi-Yu Chen
Förderung
- A technology Project of Guangzhou
- Canadian Institute for Health Research (CIHR) Project
Zitieren
APA
Zhou, Z., Chen, Q. Y., Zhuo, M., & Xu, P. Y. (2024). Inhibition of calcium-stimulated adenylyl cyclase subtype 1 (AC1) for the treatment of pain and anxiety symptoms in Parkinson’s disease mice model. Molecular Pain. https://doi.org/10.1177/17448069241266683
Vancouver
Zhou Z, Chen QY, Zhuo M, Xu PY. Inhibition of calcium-stimulated adenylyl cyclase subtype 1 (AC1) for the treatment of pain and anxiety symptoms in Parkinson’s disease mice model. Molecular Pain. 2024. doi:10.1177/17448069241266683
BibTeX
@article{Zhou2024,
author = {Zhou, Zhaoxiang and Chen, Qi-Yu and Zhuo, Min and Xu, Ping-Yi},
title = {Inhibition of calcium-stimulated adenylyl cyclase subtype 1 (AC1) for the treatment of pain and anxiety symptoms in Parkinson’s disease mice model},
journal = {Molecular Pain},
year = {2024},
doi = {10.1177/17448069241266683}
}
EUVIMED